OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

October 6th 2021

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Dr. Burris on the Integration of Sacituzumab Govitecan in Metastatic TNBC

October 5th 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

Dr. Patel on the Role of CTLA-4 Inhibitors in NSCLC

October 5th 2021

Manish Patel, DO, discusses the role of CTLA-4 inhibitors in non–small cell lung cancer.

Dr. Girard on Real-World PFS Data With Durvalumab in NSCLC

October 5th 2021

Nicolas Girard, MD, discusses the progression-free survival data with durvalumab observed in a real-world analysis of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

Dr. Colombo on Practice-Changing KEYNOTE-826 Data in Metastatic Cervical Cancer

October 5th 2021

Nicoletta Colombo, MD, PhD, discusses efficacy achieved with the addition of pembrolizumab to chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Baz on the Role of Alkylating Agents in Relapsed/Refractory Multiple Myeloma

October 5th 2021

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

Dr. Naumann on the Evolution of Immunotherapy in Endometrial Cancer

October 5th 2021

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

Dr. Brown on the Clinical Implications of the PRIMA Trial in Ovarian Cancer

October 5th 2021

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

Dr. Nassif on the Efficacy of Early-Phase Clinical Trials in Soft Tissue Sarcoma

October 4th 2021

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Dr. Rimawi on Mitigating Interstitial Lung Disease in HER2+ Breast Cancer

October 4th 2021

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

Dr. Hamilton on the Potential Integration of Novel SERDs in ER+/HER2- Breast Cancer

October 4th 2021

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer

October 4th 2021

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Dr. Yardley on the Role of Ribociclib/Letrozole in HR+ Advanced Breast Cancer

October 4th 2021

Denise A. Yardley, MD, discusses the efficacy achieved with ribociclib plus letrozole in patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Dr. Thomas on Potential Biomarkers of Response to Berzosertib/Topotecan in SCLC

October 4th 2021

Anish Thomas, MD, discusses potential biomarkers of response to the combination of berzosertib plus topotecan in patients with relapsed, platinum-resistant small cell lung cancer.

Dr. Popat on the Clinical Implications of the Final Results of the ALTA-1L Trial in ALK+ NSCLC

October 4th 2021

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.

Dr. Spira on the Role of Frontline Brigatinib in ALK+ NSCLC

October 4th 2021

Alexander I. Spira, MD, PhD, FACP, discusses the role of frontline brigatinib in ALK-positive non–small cell lung cancer.

Dr. Shah on the FDA Approval of Brexucabtagene Autoleucel for B-Cell ALL

October 1st 2021

Bijal Shah, MD, MS, discusses the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Secord on Treating Patients with Platinum Sensitive Ovarian Cancer

October 1st 2021

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

October 1st 2021

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.